ATEMPT 2.0: Adjuvant T-DM1 vs TH
Sponsored by Dana-Farber Cancer Institute
About this study
This research study is studying how well newly diagnosed breast cancer that has tested positive for a protein called HER2 responds using one of two different combination of HER2-directed therapies as a treatment after surgery. The name of the study drugs involved are: * Trastuzumab-emtansine (T-DM1, Kadcyla) * Trastuzumab SC (Herceptin Hylecta) * Paclitaxel
Enrolling at this location
Solinsky Center for Cancer Care (NH Oncology-Hematology, PA)
Manchester, New Hampshire
I'm interestedThis study also enrolls at 52 other locations. See all.
Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.
Trial data sourced from ClinicalTrials.gov.